Curatis Partners with Neupharma for Corticorelin Development in Japan's Brain Edema Market
Key Insights
Curatis and Neupharma have signed an exclusive licensing agreement for corticorelin (C-PTBE-01) to treat peritumoral brain edema (search) in Japan, with potential payments up to CHF 83.5 million plus royalties.
The drug targets a significant unmet medical need, as peritumoral brain edema (search) affects an estimated 60,000 patients in Japan and 500,000 worldwide, with no approved targeted therapies currently available.
Corticorelin has demonstrated potential to reduce or replace corticosteroid use in clinical studies, potentially avoiding severe side effects while maintaining cancer treatment efficacy.
Swiss pharmaceutical company Curatis Holding AG (search) has entered into an exclusive licensing agreement with Tokyo-based Neupharma Co., Ltd. (search) for the development and commercialization of corticorelin (C-PTBE-01) in Japan, targeting the treatment of peritumoral brain edema (search) (PTBE), a serious tumor-associated condition with no approved targeted therapies.
Financial Terms and Market Opportunity
Under the agreement announced in March 2026, Neupharma will receive exclusive rights to develop and commercialize corticorelin for PTBE treatment in Japan. Curatis stands to receive upfront and milestone payments totaling up to CHF 83.5 million for achieving regulatory and commercial targets, plus royalties on future Japanese sales of up to 20%.
The market opportunity is substantial, with an estimated 60,000 patients eligible for corticorelin treatment in Japan and 500,000 worldwide. Global market potential is forecasted to exceed USD 1 billion annually, with the US market alone representing more than 150,000 PTBE patients.
Addressing Critical Unmet Medical Need
Peritumoral brain edema (search) occurs in association with many primary and metastatic brain tumors (search), often connected to metastases from lung cancer (search), breast cancer (search), melanoma (search), and colorectal cancer (search). The condition results in brain function impairment due to extracellular fluid accumulation around tumors, causing symptoms including headaches, vomiting, and neurological dysfunction such as paralysis, speech disorders, visual problems, and altered mental status.
Current standard of care relies on corticosteroids (search), which carry serious side effects including severe myopathy, impaired glucose metabolism, muscle wasting, abnormal weight gain, osteoporosis, gastritis, gastrointestinal bleeding, hypertension, and personality changes. Additionally, corticosteroids can counteract cancer therapies such as chemotherapy or immunotherapies that depend on adequate T-cell functionality.
Corticorelin's Therapeutic Potential
Corticorelin (hCRH), a 41 amino acid endogenous polypeptide, has demonstrated preclinically the ability to positively impact the blood-brain barrier (search) after disruption due to underlying malignant tumors. In two clinical studies involving PTBE patients, corticorelin showed potential to substantially reduce or completely replace steroid use, potentially reducing or avoiding severe glucocorticoid-related side effects and improving quality of life.
Development Timeline and Strategy
The agreement stipulates that corticorelin will initially be introduced in Japan for children and adolescents. Neupharma will finance and conduct a pivotal clinical trial to support regulatory filing in Japan. A meeting with the Japanese drug regulatory authority PMDA to discuss the registration enabling study is planned for summer 2026, with the clinical study expected to commence in 2027.
Simultaneously, Curatis continues preparatory work for a pivotal Phase 3 study for approval in the US and Europe, alongside ongoing global partnering activities.
Strategic Partnership Benefits
Japan represents one of the world's most important pharmaceutical markets after the US and Europe. Neupharma brings extensive experience in developing and successfully commercializing orphan drugs and specialty care medicines in Japan, including a blockbuster drug, across oncology, immunology, pulmonology, and cardiology disorders.
Curatis Holding AG (search), a publicly listed company focused on late-stage development and commercialization of drugs for rare diseases and specialty care, maintains a sales portfolio of more than 40 products and a pipeline of orphan and specialty drugs. The company emphasizes that corticorelin remains an investigational drug not approved for therapeutic use in the United States or internationally.